Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate

NACompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

July 3, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Type 2 DiabetesCardiovascular DiseasesPharmacogenomic Drug Interaction

Interventions

DRUG

Fenofibrate 145 mg

1 tablet per day

DRUG

Placebo

1 tablet per day

Trial Locations (1)

University Hospital of Padova, Padua

All Listed Sponsors

lead

Mario Luca Morieri

OTHER